Overview

Drug-drug Interaction Study

Status:
Completed

Trial end date:
2013-01-04

Target enrollment:

Participant gender:

Summary

This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.

Phase:

Phase 2

Details

Lead Sponsor:

Amicus Therapeutics

Treatments:

1-Deoxynojirimycin